...
首页> 外文期刊>Journal of Clinical Oncology >Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
【24h】

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.

机译:下一代测序揭示了原发性肿瘤与非小细胞肺癌患者转移灶之间复发性体细胞改变的高度一致性。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE Characterization of the genomic changes that drive an individual patient's disease is critical in management of many cancers. In patients with non-small-cell lung cancer (NSCLC), obtaining tumor samples of sufficient size for genomic profiling on recurrence is often challenging. We undertook this study to compare genomic alterations identified in archived primary tumors from patients with NSCLC with those identified in metachronous or synchronous metastases. PATIENTS AND METHODS Primary and matched metastatic tumor pairs from 15 patients were analyzed by using a targeted next-generation sequencing assay in a Clinical Laboratory Improvement Amendments laboratory. Genomic libraries were captured for 3,230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to high coverage. Results Among 30 tumors, 311 genomic alterations were identified of which 63 were known recurrent (32 in primary tumor, 31 in metastasis) and 248 were nonrecurrent (likely passenger). TP53 mutations were the most frequently observed recurrent alterations (12 patients). Tumors harbored two or more (maximum four) recurrent alterations in 10 patients. Comparative analysis of recurrent alterations between primary tumor and matched metastasis revealed a concordance rate of 94% compared with 63% for likely passenger alterations. CONCLUSION This high concordance suggests that for the purposes of genomic profiling, use of archived primary tumor can identify the key recurrent somatic alterations present in matched NSCLC metastases and may provide much of the relevant genomic information required to guide treatment on recurrence.
机译:目的表征驱动个体患者疾病的基因组变化对许多癌症的治疗至关重要。在患有非小细胞肺癌(NSCLC)的患者中,获得足够大小的肿瘤样本以进行复发时的基因组分析通常是一项挑战。我们进行了这项研究,以比较在NSCLC患者的存档原发肿瘤中鉴定出的基因组改变与在同步或同步转移中鉴定出的基因组改变。患者和方法在临床实验室改进修正实验室中,使用靶向下一代测序分析法对15例患者的原发性和配对转移性肿瘤进行了分析。捕获了182个与癌症相关的基因中的3,230个外显子的基因组文库,以及来自14个基因的37个内含子,这些内含子通常在癌症中进行了重排并进行了高覆盖率测序。结果在30个肿瘤中,鉴定出311个基因组改变,其中63个已知复发(原发肿瘤32个,转移31个)和248个非复发(可能是过客的)。 TP53突变是最常见的复发性改变(12例患者)。肿瘤在10例患者中出现了两个或多个(最多四个)复发性改变。对原发性肿瘤与匹配转移之间复发性改变的比较分析显示,一致性率为94%,而可能的乘客改变为63%。结论这种高度的一致性表明,出于基因组图谱分析的目的,使用存档的原发性肿瘤可以确定匹配的NSCLC转移灶中存在的关键的复发性体细胞改变,并且可以提供指导复发治疗所需的许多相关基因组信息。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号